HSP90AA1
Heat shock protein HSP 90-alpha
As of the edition of 20 October 2026, HSP90AA1 (heat shock protein HSP 90-alpha, UniProt P07900) has 18 drugs tested at it and 16 companies on the list, 14 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P07900
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 450
- Disease areas
- Cancer; Blood and lymph; Immune system; Skin and connective tissue; Lungs and airways; Digestive system; Urinary and reproductive; Heart and blood vessels
- Registered trials of its drugs
- 175
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 7 |
| Stopped | 10 |
| Total | 18 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ganetespib | Stopped | Phase 3 | none listed |
| Tanespimycin | Stopped | Phase 3 | none listed |
| Luminespib | Went quiet | Phase 2 | none listed |
| Onalespib | Stopped | Phase 2 | none listed |
| Retaspimycin | Went quiet | Phase 3 | none listed |
| SNX 5422 | Stopped | Phase 2 | none listed |
| Alvespimycin | Stopped | Phase 2 | none listed |
| CD24FC | Stopped | Phase 3 | none listed |
| BIIB021 | Went quiet | Phase 2 | none listed |
| PU-H71 | Stopped | Phase 2 | none listed |
| TAS-116 | Marketed | Phase 1 | none listed |
| XL-888 | Went quiet | Phase 1 | none listed |
12 of 18 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 14 |
| Route B | 1 |
| Engaged | 1 |
| Total on the list | 16 |
| Company | Route |
|---|---|
| AstraZeneca | Route A |
| Bristol Myers Squibb | Route A |
| Novartis | Route A |
The other 13 companies at HSP90AA1
In the product16 companies in all; 13 are not named here, and no score is.
See the 16 companies at HSP90AA1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.